Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

Experimental Hematology

Volumn 31, Issue 8, 2003, Pages 686-692

  Akin, Cem ^a   Brockow, Knut ^a   D'Ambrosio, Claudio ^a   Kirshenbaum, Arnold S ^a   Ma, Yongsheng ^b   Longley, B Jack ^b   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MUTANT PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW CULTURE; CELL COUNT; CELL DEATH; CELL GROWTH; CLINICAL ARTICLE; CODON; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL LINE; MALE; MAST CELL LEUKEMIA; MUTATION; PRIORITY JOURNAL; WILD TYPE;

EID: 0043169405     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00112-7     Document Type: Article

References (27)

1. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 92:1995;10560-10564.
2. Longley B.J. Jr., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 96:1999;1609-1614.
3. Ma Y., Carter E., Wang X., et al. Indolinone derivatives inhibit constitutively activated kit mutants and kill neoplastic mast cells. J Invest Dermatol. 114:2000;392-394.
4. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
5. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl-positive cells. Nat Med. 2:1996;561-566.
6. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:2000;139-145.
7. Carroll M., Ohno-Jones S., Tamura S., et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 90:1997;4947-4952.
8. + leukemic cells and induces apoptosis. Blood Cells Mol Dis. 23:1997;380-394.
9. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 344:2001;1038-1042.
10. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
11. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 99:2002;1741-1744.
12. Escribano L., Orfao A., Diaz-Agustin B., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 91:1998;2731-2736.
13. +, and expresses aminopeptidase N (CD13). Blood. 94:1999;2333-2342.
14. Yavuz A.S., Lipsky P.E., Yavuz S., Metcalfe D.D., Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 100:2002;661-665.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:1983;55-63.
16. Akin C., Kirshenbaum A.S., Semere T., et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 28:2000;140-147.
17. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
18. Gari M., Goodeve A., Wilson G., et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 105:1999;894-900.
19. Beghini A., Peterlongo P., Ripamonti C.B., et al. c-kit mutations in core binding factor leukemias. Blood. 95:2000;726-727.
20. Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 154:1999;1643-1647.
21. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
22. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 12:1996;312-314.
23. Longley B.J., Ma Y., Carter E., McMahon G. New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors. Hematol Oncol Clin North Am. 14:2000;689-695.
24. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
25. Yanagida M., Fukamachi H., Ohgami K., et al. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood. 86:1995;3705-3714.
26. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 6:2000;3319-3326.
27. Wang W.L., Healy M.E., Sattler M., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19:2000;3521-3528.